Comparative Study of Potential for Bisphosphonates to Damage Gastric Mucosa of Rats
- Cite this article as:
- Peter, C.P., Kindt, M.V. & Majka, J.A. Dig Dis Sci (1998) 43: 1009. doi:10.1023/A:1018826600877
- 84 Downloads
Bisphosphonates have generally few clinicaladverse effects, the most common being gastrointestinaldisturbances. It is generally believed thatbisphosphonates with a primary amine are more irritatingto the gastrointestinal tract than those withouta primary amine. The objective of this study was tocompare the gastric irritation potential of an aminobisphosphonate (alendronate) to that of two nonamino bisphosphonates (risedronate and etidronate) ina rat model at pharmacologically equivalent andclinically relevant doses. The doses used were 1, 5, 10,and 30 mg/kg/day for alendronate and risedronate and 40, 200, 400, and 1200 mg/kg/day foretidronate. These doses represent 5-150 times therecommended clinical dose. The drugs were given orally,daily by gavage for four weeks. The gastric irritation potential was assessed by gross and microscopicevaluation of multiple sections of the stomach. Thisstudy showed that, at pharmacologically equivalentdoses, the gastric irritation potential for alendronate is no greater than that for etidronate orrisedronate.